Saturday, October 31, 2026

US Treasury Yield Spike Wipes 19.5% From Broadcom as Global Tech Stocks Reel

Broadcom lost 19.5% between June 3–5, 2026, as the US 2-year Treasury yield hit a 16-month high — triggering a synchronized selloff across global tech markets despite strong AI demand signals. NVIDIA fell 6% in a single session, Meta shed 6%, and the leveraged FNGU ETF collapsed 22%. Dell's $24 billion in AI server bookings for Q1 suggests the drop reflects rate pressure, not an AI spending reversal.

LM Salvado
LM Salvado

June 9, 2026

US Treasury Yield Spike Wipes 19.5% From Broadcom as Global Tech Stocks Reel
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Broadcom lost 19.5% between June 3–5, 2026, as the US 2-year Treasury yield surged to a 16-month high — pulling down technology stocks from New York to Tokyo.1 NVIDIA dropped 6% on June 5 alone. Meta shed 6% across the same stretch. The leveraged FNGU ETF, tracking mega-cap tech, collapsed 22% over five days.1

Rising short-term US yields tighten financial conditions globally. When American Treasuries offer higher risk-free returns, capital rotates out of high-multiple growth equities worldwide — a mechanism felt as acutely in Frankfurt and Seoul as on Wall Street.

Broadcom's own guidance undermines any AI-demand explanation for the drop. The company raised its Q3 FY26 AI semiconductor forecast during the selloff.1 Customers pulling back on chip orders do not produce upward guidance revisions. The data points in opposite directions.

NVIDIA faces the same disconnect. AI infrastructure spending indicators held firm through the period, yet shares fell with the broader sector. When leading semiconductor companies decline in unison on a bond yield print — not on earnings warnings — macro rate sensitivity is the cleaner explanation.

Dell's Q1 results reinforce that picture. The company reported $24 billion in AI server order bookings and raised its full-year revenue guidance to approximately $60 billion.1 Global hyperscalers and sovereign AI initiatives across the Gulf, Asia, and Europe are sustaining that pipeline. Order backlogs of that scale do not accumulate during a genuine AI spending freeze.

The distinction carries real consequence for international investors. A rate-driven selloff is mean-reverting if yields stabilize or retreat. A fundamentals-driven decline — customers canceling AI infrastructure budgets — requires earnings downgrades and a longer recovery. Current evidence favors the former.

AI earnings revisions across the sector have not turned negative. Until they do, sharp price declines during yield spikes are valuation compression, not business deterioration. Investors reading a structural AI slowdown into this data are misreading the signal.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com